Acrux Limited (ASX:ACR) Launches 90 Gram Dapsone 5% Gel in US
Product Launch Announcement
Acrux Limited (ASX:ACR) and its partner TruPharma have launched a 90 gram pack size of Dapsone 5%, Gel in the United States. This topical prescription medicine is aimed at treating acne vulgaris and taps into an annual U.S. market exceeding US$15.8 million (AUD$24 million) for the 12 months ending August 2024, according to IQVIA data.
Market Impact and Competitive Profile
Michael Kotsanis, CEO and Managing Director of Acrux, noted the strategic importance of this launch. “While the market for the 90 gram pack size represents only 16% of volume for the product, offering both pack sizes will improve the product’s competitive profile…” he stated. Kotsanis anticipates that this addition will positively impact the market share for Dapsone 5% Gel.
Company Background
Acrux is a specialty pharmaceutical company with extensive experience in developing and commercialising topical pharmaceutical products. The company hopes to be well-positioned to leverage its capabilities for future growth in the U.S. market.
Motley Fool contributor Aaron Shaw has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.